Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and agingLinda S. Steelman, James A. McCubrey, William H. Chappell et al.|Aging|2011Cited by 707
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human HealthWilliam H. Chappell, James A. McCubrey, María Clorinda Mazzarino et al.|Oncotarget|2011Cited by 579
GSK-3 as potential target for therapeutic intervention in cancerJames A. McCubrey, Melchiorre Cervello, Linda S. Steelman et al.|Oncotarget|2014Cited by 508
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome ResistanceJames A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Oncotarget|2012Cited by 317
Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades Which Alter Therapy Response.James A. McCubrey, Alberto M. Martelli, Linda S. Steelman et al.|Oncotarget|2012Cited by 307